Answers are grounded in this paper and cite their sources.
PURPOSE: Clinical studies suggest that estradiol combined with norethisterone (E2/NET) may increase breast cancer risk, and PGRMC1 plays a crucial function in this process. According to previous research, we demonstrated that E2/NET stimulated the proliferation of PGRMC1-overexpressing breast cancer (BC) cells. This in vitro study aimed to investigate the mechanism of microRNA-181a's anti-tumor effects on PGRMC1-overexpressing BC cells treated with E2/NET. METHODS: Stable PGRMC1-overexpressing MCF7 and T47D breast cancer cell models were established to analyze cell viability, cell proliferation, colony formation, and cell migration, to characterize miR-181a's anti-tumor effects on BC cells with E2/NET exposure. qRT-PCR and Western blot were performed to measure the expression of PGRMC1, PGRMC2, G3BP2, Pairbp1, NF-kB, and BAX at gene and protein levels. Luciferase reporter assays were performed to evaluate miR-181a binding to 3'UTR of PGRMC2 and G3BP2. RESULTS: Overexpression of miR-181a significantly reduced PGRMC1-overexpressing MCF7 cell viability, proliferation, and migration. Substantially decreased gene expression of PGRMC1, PGRMC2, G3BP2, Pairbp1, and NF-kB, and increased BAX in miR-181a-treated cells. MiR-181a inhibited PGRMC1 signaling through directly targeting PGRMC2 and G3BP2 and upregulating pro-apoptotic BAX. CONCLUSION: We reported evidence that miR-181a reduces the PGRMC1-overexpressing cell viability and upregulates pro-apoptotic BAX expression. MiR-181a can inhibit E2 combined with NET-induced PGRMC1, PGRMC2, and G3BP2 complex, thereby reducing the proliferation and migration effect of breast cancer cells treated with E2/NET.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: